DekaBank Deutsche Girozentrale Cuts Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

DekaBank Deutsche Girozentrale lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 2.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 729,128 shares of the biopharmaceutical company’s stock after selling 20,216 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.12% of Royalty Pharma worth $19,310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in RPRX. Truist Financial Corp purchased a new stake in shares of Royalty Pharma during the 4th quarter worth approximately $443,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Royalty Pharma by 0.7% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 186,763 shares of the biopharmaceutical company’s stock valued at $5,181,000 after buying an additional 1,223 shares during the period. Quadrant Capital Group LLC lifted its position in shares of Royalty Pharma by 295.8% during the 4th quarter. Quadrant Capital Group LLC now owns 3,487 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 2,606 shares during the last quarter. Kingsview Wealth Management LLC bought a new position in shares of Royalty Pharma during the 4th quarter worth $1,280,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Royalty Pharma by 87.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 15,328 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 7,132 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Morgan Stanley upped their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Monday, September 9th. The Goldman Sachs Group boosted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a report on Monday, June 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $27.72 on Monday. The company’s 50 day simple moving average is $27.80 and its two-hundred day simple moving average is $28.04. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. Royalty Pharma plc has a 1 year low of $25.20 and a 1 year high of $31.66. The stock has a market capitalization of $16.45 billion, a PE ratio of 20.69, a P/E/G ratio of 4.06 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. During the same quarter last year, the business posted $0.85 earnings per share. Analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.